News

April 7, 2022 - The fusion of new therapeutics, imaging, and biomarker development is directing us into an advanced realm of healthcare delivery. Imaging Endpoints understands that every data point counts and is critical for successful trial completion, from Phase…   Read More

March 31, 2022 - Imaging Endpoints congratulates Novartis for its recent Food and Drug Administration (FDA) approval of Locametz® and Pluvicto™. The FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with prostate-specific membrane antigen…   Read More

March 23, 2022 - Last week Imaging Endpoints had a great opportunity to join the entire stakeholder community at the Immuno-Oncology 360° Conference (“IO360”) as a founding sponsor for the 8th consecutive year. Our CMO, Ron Korn, MD, Ph.D. presented…   Read More

March 17, 2022 - Imaging Endpoints is at the IO360 Conference in New York from March 16th – 18th alongside the entire stakeholder community including scientists and experts in clinical trial design, from around the world. We’re proud that on…   Read More

March 15, 2022 - Imaging Endpoints is joining colleagues from around the world at the IO360 Conference in New York, March 16th – 18th. We proudly present our Chief Medical Officer, Ronald Korn, MD, Ph.D. deliver remarks on “Using Imaging…   Read More

March 11, 2022 - We’d love to connect at the IO360 Conference in New York between March 16th and 18th. Please drop by our booth in the DE Foyer (Booth #27) or visit https://calendly.com and schedule a private meeting. We’re…   Read More

March 8, 2022 - Imaging Endpoints will be at Immuno-Oncology 360° (“IO360”) from the 16th through the 18th of March. Imaging Endpoints is proud to be the lead sponsor for the 8th year in a row. IO360 provides a unique…   Read More

March 3, 2022 - Imaging Endpoints was founded to connect Imaging to the Cure™ and is making its vision a reality by being at the forefront of clinical trial research with ongoing clinical trials on cancer in all its forms.…   Read More

February 28, 2022 - Imaging Endpoints guides biopharma companies in protocol development and manages the central imaging review for many clinical trials aimed at the diagnosis and treatment of rare diseases. Rare Disease Day, observance on February 28, is designed…   Read More

February 24, 2022 - Immunotherapy is the most promising cancer treatment for many patients. As the world’s largest oncology focused imaging CRO, Imaging Endpoints utilizes novel response criteria, including pseudoprogression analysis, to optimize data on patient response in all phases…   Read More